Jenifer Brown1, Ian H de Boer, Cassianne Robinson-Cohen, David S Siscovick, Bryan Kestenbaum, Matthew Allison, Anand Vaidya. 1. Division of Endocrinology, Diabetes, and Hypertension (J.B., A.V.), Center for Adrenal Disorders (A.V.), Brigham and Women's Hospital and Harvard Medical School (J.B., A.V.), Boston, Massachusetts 02115; Department of Medicine, Kidney Research Institute (I.H.d.B., C.R.-C., B.K.), University of Washington, Seattle, Washington 98104; Department of Medicine, Division of Nephrology (I.H.d.B., B.K.), University of Washington, Seattle, Washington 98104; The New York Academy of Medicine (D.S.S.), New York, New York 10029; Veterans' Affairs Hospital (M.A.), San Diego, California 92161; and Division of Preventive Medicine (M.A.), Department of Family and Preventive Medicine, University of California San Diego, San Diego, California 92093.
Abstract
CONTEXT: Aldosterone and PTH are implicated in the pathogenesis of cardiovascular and skeletal diseases. An expanding body of evidence supports a bidirectional and positive physiologic relationship between aldosterone and PTH. Large population-based studies confirming this relationship, and whether it may be targeted as a potential method to mitigate the clinical consequences associated with excess aldosterone and PTH, are needed. OBJECTIVE: We hypothesized that higher aldosterone levels would associate with higher PTH, and that the use of renin-angiotensin-aldosterone system (RAAS) inhibitors would predict lower PTH in a large, multi-ethnic, community-based cohort. DESIGN, SETTING, PARTICIPANTS: We conducted cross-sectional analyses of participants in the Multi-Ethnic Study of Atherosclerosis without apparent primary hyperparathyroidism or chronic kidney disease (n = 5668). We evaluated associations of RAAS inhibitor use with PTH concentration among 1888 treated hypertensive participants. We also tested associations of serum aldosterone concentration with PTH concentration among 1547 participants with these measurements. OUTCOME: Serum PTH concentration. RESULTS: Higher aldosterone associated with higher PTH (β = 0.19 pg/ml per 1 ng/dl of aldosterone, P < .0001), and this finding was most pronounced among those with a primary hyperaldosteronism-like phenotype. There was a stepwise increment in PTH when comparing untreated normotensives, hypertensives using RAAS inhibitors, untreated hypertensives, and treated hypertensives using non-RAAS inhibitors (40.8, 45.0, 46.2, 47.1 pg/ml, respectively). The use of any RAAS inhibitor independently associated with lower PTH (β = -2.327 pg/ml per use of RAAS inhibitor, P = .006), when compared with the use of any non-RAAS inhibitor medication. CONCLUSIONS: Higher serum aldosterone concentration is associated with higher serum PTH concentration, and the use of RAAS inhibitors is associated with lower PTH concentration. These results extend prior evidence from observational and intervention studies suggesting a potentially important and modifiable relationship between the RAAS and PTH in humans.
CONTEXT: Aldosterone and PTH are implicated in the pathogenesis of cardiovascular and skeletal diseases. An expanding body of evidence supports a bidirectional and positive physiologic relationship between aldosterone and PTH. Large population-based studies confirming this relationship, and whether it may be targeted as a potential method to mitigate the clinical consequences associated with excess aldosterone and PTH, are needed. OBJECTIVE: We hypothesized that higher aldosterone levels would associate with higher PTH, and that the use of renin-angiotensin-aldosterone system (RAAS) inhibitors would predict lower PTH in a large, multi-ethnic, community-based cohort. DESIGN, SETTING, PARTICIPANTS: We conducted cross-sectional analyses of participants in the Multi-Ethnic Study of Atherosclerosis without apparent primary hyperparathyroidism or chronic kidney disease (n = 5668). We evaluated associations of RAAS inhibitor use with PTH concentration among 1888 treated hypertensiveparticipants. We also tested associations of serum aldosterone concentration with PTH concentration among 1547 participants with these measurements. OUTCOME: Serum PTH concentration. RESULTS: Higher aldosterone associated with higher PTH (β = 0.19 pg/ml per 1 ng/dl of aldosterone, P < .0001), and this finding was most pronounced among those with a primary hyperaldosteronism-like phenotype. There was a stepwise increment in PTH when comparing untreated normotensives, hypertensives using RAAS inhibitors, untreated hypertensives, and treated hypertensives using non-RAAS inhibitors (40.8, 45.0, 46.2, 47.1 pg/ml, respectively). The use of any RAAS inhibitor independently associated with lower PTH (β = -2.327 pg/ml per use of RAAS inhibitor, P = .006), when compared with the use of any non-RAAS inhibitor medication. CONCLUSIONS: Higher serum aldosterone concentration is associated with higher serum PTH concentration, and the use of RAAS inhibitors is associated with lower PTH concentration. These results extend prior evidence from observational and intervention studies suggesting a potentially important and modifiable relationship between the RAAS and PTH in humans.
Authors: Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Andreas Meinitzer; Bernhard O Boehm; Winfried März Journal: Eur Heart J Date: 2010-03-02 Impact factor: 29.983
Authors: Jenifer M Brown; Jonathan S Williams; James M Luther; Rajesh Garg; Amanda E Garza; Luminita H Pojoga; Daniel T Ruan; Gordon H Williams; Gail K Adler; Anand Vaidya Journal: Hypertension Date: 2013-11-04 Impact factor: 10.190
Authors: L Ceccoli; V Ronconi; L Giovannini; M Marcheggiani; F Turchi; M Boscaro; G Giacchetti Journal: Osteoporos Int Date: 2013-05-22 Impact factor: 4.507
Authors: Luigi Petramala; Laura Zinnamosca; Amina Settevendemmie; Cristiano Marinelli; Matteo Nardi; Antonio Concistrè; Francesco Corpaci; Gianfranco Tonnarini; Giorgio De Toma; Claudio Letizia Journal: Int J Endocrinol Date: 2014-04-03 Impact factor: 3.257
Authors: Anand Vaidya; Gary C Curhan; Julie M Paik; Henry Kronenberg; Eric N Taylor Journal: J Clin Endocrinol Metab Date: 2015-04-17 Impact factor: 5.958
Authors: Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price Journal: Endocrine Date: 2018-08-02 Impact factor: 3.633
Authors: Jenifer M Brown; Cassianne Robinson-Cohen; Miguel Angel Luque-Fernandez; Matthew A Allison; Rene Baudrand; Joachim H Ix; Bryan Kestenbaum; Ian H de Boer; Anand Vaidya Journal: Ann Intern Med Date: 2017-10-10 Impact factor: 25.391